1. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
A phase 3 trial assessed capivasertib combined with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer. The combination significantly improved progression-free survival compared to placebo plus fulvestrant, with notable benefits in patients harboring AKT pathway alterations.
2. Capivasertib Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
This randomized phase 2 trial evaluated capivasertib with paclitaxel versus placebo with paclitaxel in untreated metastatic triple-negative breast cancer. The addition of capivasertib led to improved progression-free and overall survival, especially in patients with PI3K/AKT pathway alterations.
3. The Emerging Role of Capivasertib in Breast Cancer
A comprehensive review highlighted capivasertib’s potential across breast cancer subtypes, emphasizing its efficacy in tumors with aberrant PI3K/AKT signaling. Ongoing trials are further exploring its role in combination therapies.
4. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
This nonrandomized trial focused on capivasertib’s activity in patients with tumors harboring the AKT1 E17K mutation. The study reported a modest overall response rate, suggesting limited single-agent activity in heavily pretreated populations.
